Patients with germ cell tumors relapsing from or refractory to cisplatin-based chemotherapy have a poor prognosis. To date, there is no standard salvage therapy in this scenario. We report on a heavily treated patient with germ cell tumor refractory to cisplatin-based chemotherapy and the combination of gemcitabine plus oxaliplatin. The patient had a good response to low dose of bevacizumab in combination with weekly paclitaxel with a progression-free interval of 17 months. The role of angiogenesis and anti-angiogenic therapy in germ cell tumor is discussed. We suggest that the combination of bevacizumab and paclitaxel is feasible, well tolerated, and merits further clinical investigation.